falsefalse

Navigating CML Treatment: A Patient-Centered Approach - Episode 1

Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

,

Panelists discuss how in standard clinical practice, response to first-line tyrosine kinase inhibitor therapy is monitored through regular molecular testing of BCR::ABL1 transcript levels, with key evaluations to assess whether patients achieve target milestone responses that predict long-term outcomes.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • The NCCN guidelines had recent updates for evaluating early treatment response milestones. In a patient on first-line tyrosine kinase inhibitor, how do you monitor and evaluate response in your clinical practice?
    x